Search

Your search keyword '"Liedtke, Michaela"' showing total 766 results
Start Over Author "Liedtke, Michaela"
766 results on '"Liedtke, Michaela"'

151. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Hillengass, Jens, additional, Liedtke, Michaela, additional, Baljevic, Muhamed, additional, Campagnaro, Erica, additional, Castillo, Jorge J., additional, Chandler, Jason C., additional, Cornell, Robert F., additional, Costello, Caitlin, additional, Efebera, Yvonne, additional, Faiman, Matthew, additional, Garfall, Alfred, additional, Godby, Kelly, additional, Holmberg, Leona, additional, Htut, Myo, additional, Huff, Carol Ann, additional, Kang, Yubin, additional, Landgren, Ola, additional, Malek, Ehsan, additional, Martin, Thomas, additional, Omel, James, additional, Raje, Noopur, additional, Sborov, Douglas, additional, Singhal, Seema, additional, Stockerl-Goldstein, Keith, additional, Tan, Carlyn, additional, Weber, Donna, additional, Johnson-Chilla, Alyse, additional, Keller, Jennifer, additional, and Kumar, Rashmi, additional

Published
2019
Full Text
View/download PDF

153. A single cell framework for multi-omic analysis of disease identifies malignant regulatory signatures in mixed phenotype acute leukemia

Author

Granja, Jeffrey M., primary, Klemm, Sandy, additional, McGinnis, Lisa M., additional, Kathiria, Arwa S., additional, Mezger, Anja, additional, Parks, Benjamin, additional, Gars, Eric, additional, Liedtke, Michaela, additional, Zheng, Grace X.Y., additional, Chang, Howard Y., additional, Majeti, Ravindra, additional, and Greenleaf, William J., additional

Published
2019
Full Text
View/download PDF

156. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Author

Raje, Noopur, primary, Berdeja, Jesus, additional, Lin, Yi, additional, Siegel, David, additional, Jagannath, Sundar, additional, Madduri, Deepu, additional, Liedtke, Michaela, additional, Rosenblatt, Jacalyn, additional, Maus, Marcela V., additional, Turka, Ashley, additional, Lam, Lyh-Ping, additional, Morgan, Richard A., additional, Friedman, Kevin, additional, Massaro, Monica, additional, Wang, Julie, additional, Russotti, Greg, additional, Yang, Zhihong, additional, Campbell, Timothy, additional, Hege, Kristen, additional, Petrocca, Fabio, additional, Quigley, M. Travis, additional, Munshi, Nikhil, additional, and Kochenderfer, James N., additional

Published
2019
Full Text
View/download PDF

157. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin

Author

Jabbour, Elias, primary, Advani, Anjali S., additional, Stelljes, Matthias, additional, Stock, Wendy, additional, Liedtke, Michaela, additional, Gökbuget, Nicola, additional, Martinelli, Giovanni, additional, O'Brien, Susan, additional, White, Jane Liang, additional, Wang, Tao, additional, Luisa Paccagnella, M., additional, Sleight, Barbara, additional, Vandendries, Erik, additional, DeAngelo, Daniel J., additional, and Kantarjian, Hagop M., additional

Published
2019
Full Text
View/download PDF

161. Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.

Author

Badar, Talha, Szabo, Aniko, Dinner, Shira, Liedtke, Michaela, Burkart, Madelyn, Shallis, Rory M., Yurkiewicz, Ilana R., Kuo, Eric, Khan, Muhammad Ali, Balasubramanian, Suresh, Yang, Jay, Hefazi, Mehrdad, Podoltsev, Nikolai, Patel, Anand, Curran, Emily, Wang, Amy, Arslan, Shukaib, Aldoss, Ibrahim, Siebenaller, Caitlin, and Mattison, Ryan J.

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, HEMATOPOIETIC stem cell transplantation, MEDICAL personnel, TERMINATION of treatment
Abstract

Background: The availability of novel agents (NAs), including blinatumomab and inotuzumab ozogamicin (InO), has improved the outcomes of patients with relapsed/refractory (RR) B‐cell acute lymphoblastic leukemia (ALL). Because of the relative effectiveness, it is often a challenge for clinicians to determine how to best sequence these NAs with respect to efficacy and toxicity. Methods: In this multicenter, retrospective study of patients with RR ALL treated with blinatumomab, InO, or both, their efficacy as a first or second NA was compared. Results: Among 276 patients, 221 and 55 received blinatumomab and InO, respectively, as a first NA therapy. The complete remission (CR)/complete remission with incomplete count recovery (CRi) rate was 65% and 67% for the blinatumomab and InO groups, respectively (P =.73). The rate of treatment discontinuation due to adverse events was 4% and 7% in the blinatumomab and InO groups, respectively. Ninety‐two patients (43%) in the blinatumomab group and 13 patients (29%) in the InO group proceeded with allogeneic hematopoietic stem cell transplantation. The median overall survival (OS) was 15 and 11.6 months in the blinatumomab and InO groups, respectively. A subset analysis was performed for 61 patients who received both NAs (blinatumomab and then InO [n = 40] or InO and then blinatumomab [n = 21]). The CR/CRi rate was 58% for patients who received InO as the second NA and 52% for patients who received blinatumomab as the second NA. The median OS was 10.5 for patients who received InO as the second NA and 5.9 months for patients who received blinatumomab as the second NA (P =.09). Conclusions: Although the limited power of this study to detect a significant difference between subgroups is acknowledged, the data suggest that blinatumomab and InO may have comparable efficacy as a first or second NA therapy in RR ALL. Blinatumomab and inotuzumab ozogamicin have comparable efficacy as a first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. The sequencing of these novel agents should be tailored according to individual patient needs. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

163. A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701

Author

Wieduwilt, Matthew J., primary, Yin, Jun, additional, Wetzler, Meir, additional, Uy, Geoffrey L., additional, Powell, Bayard L., additional, Kolitz, Jonathan E., additional, Liedtke, Michaela, additional, Stock, Wendy, additional, Beumer, Jan H, additional, Mattison, Ryan J., additional, Storrick, Elizabeth, additional, Devine, Steven, additional, Smith, Scott E., additional, Stone, Richard M., additional, and Larson, Richard A., additional

Published
2018
Full Text
View/download PDF

165. Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment

Author

Gandhi, Ujjawal H, primary, Lakshman, Arjun, additional, Gahvari, Zhubin, additional, McGehee, Elizabeth, additional, Jagosky, Megan Helena, additional, Gupta, Ridhi, additional, Varnado, William, additional, Chhabra, Saurabh, additional, Fiala, Mark A., additional, Malek, Ehsan, additional, Mansour, Joshua, additional, Paul, Barry, additional, Barnstead, Alyssa, additional, Kodali, Saranya, additional, Neppalli, Amarendra K., additional, Liedtke, Michaela, additional, Godby, Kelly N., additional, Kang, Yubin, additional, Kansagra, Ankit, additional, Scott, Emma C., additional, Umyarova, Elvira, additional, Hari, Parameswaran, additional, Vij, Ravi, additional, Usmani, Saad Z., additional, Callander, Natalie Scott, additional, Cornell, Robert Frank, additional, Kumar, Shaji K., additional, and Costa, Luciano J, additional

Published
2018
Full Text
View/download PDF

166. Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy

Author

Cornell, Robert Frank, primary, Gandhi, Ujjawal H, additional, Lakshman, Arjun, additional, Gahvari, Zhubin, additional, Jagosky, Megan Helena, additional, McGehee, Elizabeth, additional, Varnado, William, additional, Gupta, Ridhi, additional, Chhabra, Saurabh, additional, Fiala, Mark A., additional, Malek, Ehsan, additional, Mansour, Joshua, additional, Paul, Barry, additional, Barnstead, Alyssa, additional, Kodali, Saranya, additional, Neppalli, Amarendra K., additional, Liedtke, Michaela, additional, Godby, Kelly N., additional, Kang, Yubin, additional, Kansagra, Ankit, additional, Umyarova, Elvira, additional, Scott, Emma C., additional, Hari, Parameswaran, additional, Vij, Ravi, additional, Usmani, Saad Z., additional, Callander, Natalie Scott, additional, Costa, Luciano J, additional, and Kumar, Shaji K., additional

Published
2018
Full Text
View/download PDF

167. Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies

Author

Varnado, William, primary, Jagosky, Megan Helena, additional, Gahvari, Zhubin, additional, Chhabra, Saurabh, additional, Gandhi, Ujjawal H, additional, Lakshman, Arjun, additional, McGehee, Elizabeth, additional, Gupta, Ridhi, additional, Malek, Ehsan, additional, Fiala, Mark A., additional, Mansour, Joshua, additional, Paul, Barry, additional, Barnstead, Alyssa, additional, Kodali, Saranya, additional, Amarendra, Neppalli, additional, Liedtke, Michaela, additional, Godby, Kelly N., additional, Kang, Yubin, additional, Kansgra, Ankit, additional, Scott, Emma C., additional, Umyarova, Elvira, additional, Hari, Parameswaran, additional, Vij, Ravi, additional, Usmani, Saad Z., additional, Cornell, Robert Frank, additional, Kumar, Shaji K., additional, Callander, Natalie Scott, additional, and Costa, Luciano J, additional

Published
2018
Full Text
View/download PDF

171. Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.

Author

Cassaday, Ryan Daniel, primary, DeAngelo, Daniel J., additional, Martinelli, Giovanni, additional, Stock, Wendy, additional, Stelljes, Matthias, additional, Gökbuget, Nicola, additional, Advani, Anjali S., additional, O'Brien, Susan Mary, additional, Liedtke, Michaela, additional, Merchant, Akil Abid, additional, Wang, Tao, additional, Vandendries, Erik, additional, Marks, David I., additional, Jabbour, Elias, additional, and Kantarjian, Hagop M., additional

Published
2018
Full Text
View/download PDF

172. Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%).

Author

Advani, Anjali S., primary, DeAngelo, Daniel J., additional, Marks, David I., additional, Stelljes, Matthias, additional, Liedtke, Michaela, additional, Stock, Wendy, additional, Gökbuget, Nicola, additional, O'Brien, Susan Mary, additional, Jabbour, Elias, additional, Merchant, Akil Abid, additional, Wang, Tao, additional, Vandendries, Erik, additional, Neuhof, Alexander, additional, and Kantarjian, Hagop M., additional

Published
2018
Full Text
View/download PDF

173. Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells.

Author

Munshi, Nikhil C., primary, Berdeja, Jesus G., additional, Lin, Yi, additional, Kochenderfer, James, additional, Raje, Noopur S., additional, Liedtke, Michaela, additional, Jagannath, Sundar, additional, Madduri, Deepu, additional, Rosenblatt, Jacalyn, additional, Maus, Marcela Valderrama, additional, Turka, Ashley, additional, Lam, Lyh Ping, additional, Hege, Kristen, additional, Campbell, Timothy Brandon, additional, Massaro, Monica, additional, Petrocca, Fabio, additional, and Siegel, David Samuel DiCapua, additional

Published
2018
Full Text
View/download PDF

174. bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.

Author

Raje, Noopur S., primary, Berdeja, Jesus G., additional, Lin, Yi, additional, Munshi, Nikhil C., additional, Siegel, David Samuel DiCapua, additional, Liedtke, Michaela, additional, Jagannath, Sundar, additional, Madduri, Deepu, additional, Rosenblatt, Jacalyn, additional, Maus, Marcela Valderrama, additional, Turka, Ashley, additional, Lam, Lyh Ping, additional, Morgan, Richard A., additional, Quigley, Travis, additional, Massaro, Monica, additional, Hege, Kristen, additional, Petrocca, Fabio, additional, and Kochenderfer, James, additional

Published
2018
Full Text
View/download PDF

175. Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

Author

Stock, Wendy, primary, Martinelli, Giovanni, additional, Stelljes, Matthias, additional, DeAngelo, Daniel J., additional, Gökbuget, Nicola, additional, Advani, Anjali S., additional, O'Brien, Susan Mary, additional, Liedtke, Michaela, additional, Merchant, Akil Abid, additional, Cassaday, Ryan Daniel, additional, Wang, Tao, additional, Vandendries, Erik, additional, Marks, David I., additional, and Kantarjian, Hagop M., additional

Published
2018
Full Text
View/download PDF

176. Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

Author

Jabbour, Elias, primary, Gökbuget, Nicola, additional, Advani, Anjali S., additional, Stelljes, Matthias, additional, Stock, Wendy, additional, Liedtke, Michaela, additional, Martinelli, Giovanni, additional, O'Brien, Susan Mary, additional, Wang, Tao, additional, Laird, Douglas, additional, Vandendries, Erik, additional, Neuhof, Alexander, additional, DeAngelo, Daniel J., additional, and Kantarjian, Hagop M., additional

Published
2018
Full Text
View/download PDF

177. Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells.

Author

Berdeja, Jesus G., primary, Lin, Yi, additional, Kochenderfer, James, additional, Raje, Noopur S., additional, Munshi, Nikhil C., additional, Siegel, David Samuel DiCapua, additional, Liedtke, Michaela, additional, Madduri, Deepu, additional, Rosenblatt, Jacalyn, additional, Maus, Marcela Valderrama, additional, Turka, Ashley, additional, Lam, Lyh Ping, additional, Hege, Kristen, additional, Campbell, Timothy Brandon, additional, Massaro, Monica, additional, Petrocca, Fabio, additional, and Jagannath, Sundar, additional

Published
2018
Full Text
View/download PDF

178. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE

Author

Jabbour, Elias J., primary, DeAngelo, Daniel J., additional, Stelljes, Matthias, additional, Stock, Wendy, additional, Liedtke, Michaela, additional, Gökbuget, Nicola, additional, O'Brien, Susan, additional, Wang, Tao, additional, Paccagnella, M. Luisa, additional, Sleight, Barbara, additional, Vandendries, Erik, additional, Advani, Anjali S., additional, and Kantarjian, Hagop M., additional

Published
2018
Full Text
View/download PDF

179. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Alsina, Melissa, additional, Atanackovic, Djordje, additional, Biermann, J. Sybil, additional, Castillo, Jorge, additional, Chandler, Jason C., additional, Costello, Caitlin, additional, Faiman, Matthew, additional, Fung, Henry C., additional, Godby, Kelly, additional, Hofmeister, Craig, additional, Holmberg, Leona, additional, Holstein, Sarah, additional, Huff, Carol Ann, additional, Kang, Yubin, additional, Kassim, Adetola, additional, Liedtke, Michaela, additional, Malek, Ehsan, additional, Martin, Thomas, additional, Neppalli, Vishala T., additional, Omel, James, additional, Raje, Noopur, additional, Singhal, Seema, additional, Somlo, George, additional, Stockerl-Goldstein, Keith, additional, Weber, Donna, additional, Yahalom, Joachim, additional, Kumar, Rashmi, additional, and Shead, Dorothy A., additional

Published
2018
Full Text
View/download PDF

180. Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Author

Berdeja, Jesus G., primary, Lin, Yi, additional, Raje, Noopur, additional, Munshi, Nikhil, additional, Siegel, David, additional, Liedtke, Michaela, additional, Jagannath, Sundar, additional, Maus, Marcela V., additional, Turka, Ashley, additional, Lam, Lyh Ping, additional, Hege, Kristen, additional, Morgan, Richard A., additional, Quigley, Michael Travis, additional, and Kochenderfer, James N., additional

Published
2017
Full Text
View/download PDF

181. NCCN Guidelines® Insights Multiple Myeloma, Version 3.2016: Featured Updates to the NCCN Guidelines

Author

Anderson, Kenneth C., Alsina, Melissa, Atanackovic, Djordje, Biermann, J. Sybil, Chandler, Jason C., Costello, Caitlin, Djulbegovic, Benjamin, Fung, Henry C., Gasparetto, Cristina, Godby, Kelly, Hofmeister, Craig, Holmberg, Leona, Holstein, Sarah, Huff, Carol Ann, Kassim, Adetola, Krishnan, Amrita Y., Kumar, Shaji K., Liedtke, Michaela, Lunning, Matthew, Raje, Noopur, Reu, Frederic J., Singhal, Seema, Somlo, George, Stockerl-Goldstein, Keith, Treon, Steven P., Weber, Donna, Yahalom, Joachim, Shead, Dorothy A., and Kumar, Rashmi

Subjects
hemic and lymphatic diseases, Humans, sense organs, skin and connective tissue diseases, Multiple Myeloma, Article
Abstract

These NCCN Guidelines Insights highlight the important updates/changes specific to the 2016 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include updated recommendations to the overall management of multiple myeloma from diagnosis and staging to new treatment options.

Published
2016

182. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma

Author

Lemieux, Christopher, Muffly, Lori S., Rezvani, Andrew, Lowsky, Robert, Iberri, David J., Craig, Juliana K., Frank, Matthew J., Johnston, Laura J., Liedtke, Michaela, Negrin, Robert, Weng, Wen-Kai, Meyer, Everett, Shizuru, Judith, Shiraz, Parveen, Arai, Sally, Miklos, David B., and Sidana, Surbhi

Abstract

We evaluated 79 patients with multiple myeloma (MM) =70 years referred to our blood and marrow transplant clinic, within 1 year of diagnosis from 2010 to 2019, for consideration of autologous stem cell transplant (ASCT). Thirty-eight (48%) of 79 patients underwent ASCT. ASCT was not pursued in 41 (52%) patients due to: patient or physician preference in 80% (n?=?33) or ineligibility in 20% (n?=?8). Baseline characteristics of patients in the two groups were similar. Median PFS from treatment start amongst patients undergoing ASCT (n?=?38) vs. not (n?=?41) was 41 months vs. 33 months, p?=?0.03. There was no difference in OS, with estimated 5-year OS of 73% vs. 83%, respectively (p?=?0.86). Day +100 transplant-related mortality (TRM) was 0%. ASCT was an independent favorable prognostic factor for PFS in multivariate analysis, after accounting for HCT-CI score, performance status, hematologic response, and maintenance. Finally, patients =70 years undergoing ASCT had similar PFS compared to a contemporaneous institutional cohort of patients <70 years (n?=?631) (median PFS from transplant: 36 vs. 47 months, p?=?0.25). In this retrospective analysis, ASCT was associated with low TRM and better PFS in fit older adults with MM compared to non-transplant therapy, with comparable benefits as seen in younger patients.

Published
2021
Full Text
View/download PDF

183. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

Author

Advani, Anjali S., Larsen, Eric, Laumann, Kristina, Luger, Selina M., Liedtke, Michaela, Devidas, Meenakshi, Chen, Zhiguo, Yin, Jun, Foster, Matthew C., Claxton, David, Coffan, Kristin, Tallman, Martin S., Appelbaum, Frederick R., Erba, Harry, Stone, Richard M., Hunger, Stephen P., McNeer, Jennifer L., Loh, Mignon L., Raetz, Elizabeth, Winick, Naomi, Carroll, William, Larson, Richard A., and Stock, Wendy

Abstract

Adolescents and young adults (AYAs) with acute lymphoblastic leukemia have improved outcomes when treated with pediatric-inspired regimens. CALGB 10403 was the largest prospective study to evaluate the feasibility of using a pediatric regimen in AYAs with acute lymphoblastic leukemia up to 40 years of age. This article presents the toxicity events observed in the CALGB 10403 study and compares these toxicities vs those observed among AYAs treated on the same arm of the companion Children’s Oncology Group (COG) AALL0232 study. Toxicities in CALGB 10403 were similar to those observed in COG AALL0232. Some grade 3 to 4 adverse events were more often reported in CALGB 10403 compared with COG AALL0232 (hyperglycemia, hyperbilirubinemia, transaminase elevation, and febrile neutropenia). Adverse events correlated with body mass index ≥30 kg/m2 and some with increasing age. The mortality rate in CALGB 10403 was low (4%) and similar to that in the COG AALL0232 trial. A caveat to this analysis is that only 39% of CALGB 10403 patients completed all planned protocol treatment. In COG AALL0232, although 74% of patients aged <18 years completed treatment, only 57% of patients aged ≥18 years completed treatment. This scenario suggests that issues associated with age and treating physician may be a factor. Due to its improved survival rates compared with historical controls, the CALGB 10403 regimen is now a standard of care. The hope is that the rate of protocol completion will increase as more familiarity is gained with this regimen. These trials were registered at www.clinicaltrials.gov as #NCT00558519 (CALGB 10403) and #NCT00075725 (COG AALL0232).

Published
2021
Full Text
View/download PDF

184. Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma

Author

Lemieux, Christopher, Muffly, Lori S., Iberri, David J., Craig, Juliana K., Johnston, Laura J., Lowsky, Robert, Shiraz, Parveen, Rezvani, Andrew R., Frank, Matthew J., Weng, Wen-Kai, Meyer, Everett, Shizuru, Judith A., Arai, Sally, Liedtke, Michaela, Negrin, Robert S., Miklos, David B., and Sidana, Surbhi

Abstract

We evaluated the outcomes of 168 patients undergoing delayed or second autologous stem cell transplant (ASCT) for relapsed multiple myeloma (MM) from 2010 to 2019. Overall, 21% (n= 35) patients had received a prior transplant and 69% (n= 116) underwent transplant at first relapse. Overall, 27% patients had high-risk cytogenetics and 15% had ISS stage III disease. Stem cell collection was performed after relapse in 72% and 35% of patients received maintenance therapy. Median PFS from salvage treatment and transplant were 28 and 19 months, respectively. Median OS from salvage treatment and transplant was 69 and 55 months. Multivariate analysis revealed that ASCT in first relapse was associated with superior PFS (HR 0.63, p= 0.03) and OS (HR 0.59, p= 0.04) compared to later lines of therapy. In addition, PFS of ≥36 months with prior therapy was associated with improved PFS (HR 0.62, p= 0.04) and OS (HR 0.41, p= 0.01). Ninety-five patients underwent delayed transplant at first relapse, median PFS and OS from start of therapy was 30 and 69 months, and median OS from diagnosis was 106 months. These data may serve as a guide when counseling patients undergoing ASCT for relapsed MM and provide a benchmark in designing clinical trials of transplantation/comparative treatments for relapsed MM.

Published
2021
Full Text
View/download PDF

187. Twice-weekly Ixazomib plus Lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT)

Author

Richardson, Paul, primary, Hofmeister, Craig, additional, Rosenbaum, Cara, additional, Htut, Myo, additional, Vesole, David, additional, Berdeja, Jesus, additional, Liedtke, Michaela, additional, Chari, Ajai, additional, Smith, Stephen, additional, Lebovic, Daniel, additional, Raje, Noopur, additional, Liao, Eileen, additional, Zhang, Xiaoquan, additional, Berg, Deborah, additional, and Baz, Rachid, additional

Published
2017
Full Text
View/download PDF

189. Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response

Author

Saygin, Caner, primary, Papadantonakis, Nikolaos, additional, Cassaday, Ryan D., additional, Liedtke, Michaela, additional, Fischer, Katrina, additional, Dunn, Tamara, additional, Patel, Bhumika J., additional, Sobecks, Ronald, additional, Kalaycio, Matt, additional, Sekeres, Mikkael A., additional, Mukherjee, Sudipto, additional, Gerds, Aaron T., additional, Hamilton, Betty K., additional, Carraway, Hetty E., additional, and Advani, Anjali S., additional

Published
2017
Full Text
View/download PDF

190. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

Author

DeAngelo, Daniel J., primary, Stock, Wendy, additional, Stein, Anthony S., additional, Shustov, Andrei, additional, Liedtke, Michaela, additional, Schiffer, Charles A., additional, Vandendries, Erik, additional, Liau, Katherine, additional, Ananthakrishnan, Revathi, additional, Boni, Joseph, additional, Laird, A. Douglas, additional, Fostvedt, Luke, additional, Kantarjian, Hagop M., additional, and Advani, Anjali S., additional

Published
2017
Full Text
View/download PDF

191. First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.

Author

Berdeja, Jesus G., primary, Lin, Yi, additional, Raje, Noopur S., additional, Siegel, David Samuel DiCapua, additional, Munshi, Nikhil C., additional, Liedtke, Michaela, additional, Jagannath, Sundar, additional, Maus, Marcela Valderrama, additional, Turka, Ashley, additional, Lam, Lyh Ping, additional, Hege, Kristen, additional, Morgan, Richard, additional, Quigley, M. Travis, additional, and Kochenderfer, James, additional

Published
2017
Full Text
View/download PDF

192. Impact of NEOD001 on Neuropathy in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Results From the Expansion Phase of a Phase 1/2 Study (S5.001)

Author

Liedtke, Michaela, primary, Comenzo, Raymond L., additional, Landau, Heather, additional, Sanchorawala, Vaishali, additional, Weiss, Brendan M., additional, Zonder, Jeffrey, additional, Walling, Jackie, additional, Kinney, Gene G., additional, Koller, Martin, additional, Schenk, Dale B., additional, Guthrie, Spencer D., additional, Liu, Enchi, additional, and Gertz, Morie A., additional

Published
2017
Full Text
View/download PDF

194. NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY

Author

Liedtke, Michaela, primary, Comenzo, Raymond, additional, Landau, Heather, additional, Sanchorawala, Vaishali, additional, Weiss, Brendan, additional, Zonder, Jeffrey, additional, Walling, Jackie, additional, Kinney, Gene, additional, Koller, Martin, additional, Schenk, Dale B., additional, Guthrie, Spencer, additional, Liu, Enchi, additional, and Gertz, Morie, additional

Published
2017
Full Text
View/download PDF

195. Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response

Author

Gertz, Morie A., primary, Comenzo, Raymond L., additional, Landau, Heather, additional, Sanchorawala, Vaishali, additional, Weiss, Brendan M., additional, Zonder, Jeffrey A., additional, Walling, Jackie, additional, Kinney, Gene G., additional, Koller, Martin, additional, Schenk, Dale B., additional, Guthrie, Spencer D., additional, Liu, Enchi, additional, and Liedtke, Michaela, additional

Published
2017
Full Text
View/download PDF

196. NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Results From a Phase 1/2 Study

Author

Gertz, Morie A., primary, Comenzo, Raymond L., additional, Landau, Heather, additional, Sanchorawala, Vaishali, additional, Weiss, Brendan M., additional, Zonder, Jeffrey A., additional, Walling, Jackie, additional, Kinney, Gene G., additional, Koller, Martin, additional, Schenk, Dale B., additional, Guthrie, Spencer D., additional, Liu, Enchi, additional, and Liedtke, Michaela, additional

Published
2017
Full Text
View/download PDF

197. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Alsina, Melissa, additional, Atanackovic, Djordje, additional, Biermann, J. Sybil, additional, Chandler, Jason C., additional, Costello, Caitlin, additional, Faiman, Matthew, additional, Fung, Henry C., additional, Gasparetto, Cristina, additional, Godby, Kelly, additional, Hofmeister, Craig, additional, Holmberg, Leona, additional, Holstein, Sarah, additional, Huff, Carol Ann, additional, Kassim, Adetola, additional, Liedtke, Michaela, additional, Martin, Thomas, additional, Omel, James, additional, Raje, Noopur, additional, Reu, Frederic J., additional, Singhal, Seema, additional, Somlo, George, additional, Stockerl-Goldstein, Keith, additional, Treon, Steven P., additional, Weber, Donna, additional, Yahalom, Joachim, additional, Shead, Dorothy A., additional, and Kumar, Rashmi, additional

Published
2017
Full Text
View/download PDF

198. The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction

Author

Liedtke, Michaela, primary, Merlini, Giampaolo, additional, Landau, Heather, additional, Comenzo, Raymond L., additional, Sanchorawala, Vaishali, additional, Weiss, Brendan M., additional, Zonder, Jeffrey A., additional, Walling, Jackie, additional, Kinney, Gene G., additional, Koller, Martin, additional, and Gertz, Morie A., additional

Published
2016
Full Text
View/download PDF

199. Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response

Author

Liedtke, Michaela, primary, Comenzo, Raymond L., additional, Landau, Heather, additional, Sanchorawala, Vaishali, additional, Weiss, Brendan M., additional, Zonder, Jeffrey A., additional, Walling, Jackie, additional, Kinney, Gene G., additional, Koller, Martin, additional, Schenk, Dale B., additional, Guthrie, Spencer D., additional, Liu, Enchi, additional, and Gertz, Morie A., additional

Published
2016
Full Text
View/download PDF

200. A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance)

Author

Wieduwilt, Matthew J., primary, Yin, Jun, additional, Wetzler, Meir, additional, Uy, Geoffrey L., additional, Powell, Bayard L, additional, Kolitz, Jonathan E., additional, Liedtke, Michaela, additional, Stock, Wendy, additional, Beumer, Jan H., additional, Mattison, Ryan J., additional, Halvorson, Alese, additional, Devine, Steven M., additional, Smith, Scott, additional, Stone, Richard M., additional, and Larson, Richard A., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results